Xenetic Biosciences is collaborating with PeriNess Ltd. on a study involving DNase I combined with anti-CD19 CAR T cells, with data suggesting successful degradation of NETs.
2 reports, 1 independent
Updated Jul 30
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Xenetic Biosciences is collaborating with PeriNess Ltd. on a study involving DNase I combined with anti-CD19 CAR T cells, with data suggesting successful degradation of NETs.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Xenetic Biosciences (United Kingdom)
company in London, United Kingdom
Nothing else this week.
Coverage
Newest first; wire copies grouped- ACCESS NewswireXenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma Investigator initi
- Unknown outlet